Johnson & Johnson (NYSE: JNJ) delivered stronger-than-expected second-quarter 2026 financial results, lifted its full-year revenue and earnings outlook, and reaffirmed its path toward surpassing $100 billion in annual sales for the first time. Despite these positive developments, the stock declined as investors focused on elevated expectations, patent-related revenue erosion, litigation exposure and the sustainability of future earnings growth.

Key Highlights

  • Johnson & Johnson (NYSE: JNJ) reported Q2 2026 revenue of $25.31 billion, up 6.6% year over year, while adjusted EPS of $2.90 exceeded market expectations.
  • The company raised its 2026 outlook, forecasting revenue of $100.8-$101.4 billion and adjusted EPS of $11.60-$11.75.
  • Oncology remained the primary growth driver, with cancer medicine revenue increasing around 17% to $7.41 billion, led by Darzalex, Carvykti and Rybrevant/Lazcluze.
  • JNJ shares declined about 2.7% despite the earnings beat, reflecting profit-taking following a strong year-to-date rally and investor concerns over long-term challenges.
  • Patent expirations, talc litigation, pricing pressure and concentration in newer oncology products remain key issues influencing investor sentiment.

Why Did Johnson & Johnson (NYSE: JNJ) Stock Fall Despite Strong Q2 2026 Earnings?

Johnson & Johnson (NYSE: JNJ) delivered what would typically be considered a strong quarterly report. The healthcare company exceeded analyst expectations for both revenue and earnings, raised its full-year guidance for the second time in 2026, and highlighted continued momentum across its pharmaceutical and medical technology businesses.

Nevertheless, the stock declined approximately 2.7% following the earnings announcement on July 15, 2026.

The market reaction illustrates a familiar earnings-season dynamic: strong reported results do not necessarily translate into share price gains when investors have already priced in much of the positive news. Following a roughly 22% year-to-date rally before earnings, expectations surrounding Johnson & Johnson had become increasingly demanding.

Rather than focusing solely on the improved outlook, investors weighed several longer-term issues, including the ongoing loss of exclusivity for blockbuster medicines, litigation risks and questions surrounding the sustainability of future earnings growth.

Johnson & Johnson Q2 2026 Earnings Beat Expectations

Johnson & Johnson reported second-quarter 2026 worldwide sales of $25.31 billion, representing 6.6% year-over-year growth. Operational sales increased 5.6%, while adjusted operational growth reached 5.7%.

Adjusted earnings per share came in at $2.90, increasing from $2.77 a year earlier and comfortably exceeding Wall Street expectations of roughly $2.85.

The company also demonstrated balanced growth across its two operating divisions.

Innovative Medicine

The pharmaceutical business generated:

  • Revenue of $16.38 billion
  • Reported growth of 7.8%
  • Operational growth of 6.8%

The division continued benefiting from rapid expansion in oncology therapies while offsetting declines from mature products losing market exclusivity.

MedTech

Johnson & Johnson's MedTech segment reported:

  • Revenue of $8.93 billion
  • Reported growth of 4.5%
  • Operational growth of 3.6%

Growth was supported by electrophysiology, wound closure products and biosurgery, although certain cardiovascular products experienced softer demand.

Oncology Portfolio Continues to Drive Johnson & Johnson's Growth

The strongest contributor to Johnson & Johnson's quarterly performance remained its oncology franchise.

Total cancer medicine revenue increased approximately 17% year over year to $7.41 billion, highlighting the company's successful transition toward next-generation therapies.

Several products delivered particularly strong growth.

Darzalex Remains a Blockbuster

Darzalex, used in multiple myeloma treatment, generated approximately $4.2 billion in quarterly sales, maintaining its position as one of Johnson & Johnson's largest pharmaceutical products.

The medicine continues to benefit from expanded treatment indications and increasing adoption across multiple treatment settings.

Carvykti Shows Rapid Commercial Expansion

Carvykti, the company's CAR-T cell therapy for multiple myeloma, reported quarterly sales of $657 million, representing approximately 49% year-over-year growth.

The product remains one of Johnson & Johnson's most important long-term oncology assets as manufacturing capacity continues expanding.

Rybrevant/Lazcluze Continues Strong Momentum

The lung cancer treatment combination generated approximately $289 million in quarterly sales, increasing around 61% from the prior year.

The rapid uptake reflects continued physician adoption following recent clinical data supporting broader use.

Collectively, these therapies demonstrate Johnson & Johnson's strategy of replacing aging blockbuster medicines with newer, high-growth oncology products.

Johnson & Johnson Raises Full-Year 2026 Guidance

Management increased its financial outlook for the second time this year.

The updated guidance includes:

  • Revenue: $100.8 billion-$101.4 billion
  • Midpoint approximately $101.1 billion

Previous midpoint:

  • Approximately $100.8 billion

The company also increased adjusted earnings guidance:

  • Adjusted EPS: $11.60-$11.75
  • Midpoint: $11.68

Previous guidance:

  • $11.45-$11.65
  • Midpoint: $11.55

The updated forecast implies Johnson & Johnson remains on course to exceed $100 billion in annual revenue for the first time in its history.

Chief Executive Joaquin Duato highlighted continued confidence in both Innovative Medicine and MedTech, supported by commercial execution and product launches.

Why Wall Street Still Sold Johnson & Johnson Stock

Despite improved guidance, several factors explain the negative market reaction.

1. High Expectations Were Already Reflected in the Stock

Before reporting earnings, Johnson & Johnson shares had gained roughly 22% during 2026.

When valuations already incorporate optimistic expectations, even better-than-expected results may fail to generate additional buying interest.

Instead, many investors use earnings announcements as opportunities to realize gains.

2. GAAP Profit Growth Was Limited

While adjusted earnings improved, reported profitability remained relatively flat.

Quarterly results included:

  • GAAP net earnings: $5.53 billion
  • Prior-year net earnings: $5.54 billion

GAAP diluted EPS declined slightly from:

  • $2.29
  • to $2.27

This contrast between adjusted and reported earnings may have tempered enthusiasm among investors focused on underlying profitability.

3. Stelara Revenue Decline Continues

One of Johnson & Johnson's biggest structural challenges remains the loss of exclusivity for Stelara.

Following biosimilar competition, Stelara continues experiencing meaningful revenue declines, reducing pharmaceutical growth by approximately 760 basis points during the quarter.

Although oncology products are successfully replacing much of this revenue, investors continue monitoring how quickly new therapies can offset the patent cliff.

4. Litigation Remains a Significant Overhang

Johnson & Johnson continues facing extensive talc-related litigation.

Following the rejection of its previous bankruptcy settlement strategy, the company must continue defending tens of thousands of lawsuits through the court system.

Although management has repeatedly emphasized confidence in its legal position, litigation uncertainty continues influencing investor sentiment.

5. Broader Healthcare Policy Risks Persist

Healthcare companies continue facing evolving regulatory and pricing environments.

Potential risks include:

  • Drug pricing reforms
  • Tariff-related cost pressures
  • Reimbursement changes
  • Government pricing initiatives
  • Competitive biosimilar launches

While none materially affected the quarter, investors continue incorporating these uncertainties into long-term valuation models.

Johnson & Johnson's Competitive Position Remains Strong

Johnson & Johnson competes across both pharmaceuticals and medical devices.

Within oncology, major competitors include:

Darzalex continues competing successfully in multiple myeloma, while Carvykti remains one of the leading CAR-T therapies alongside Bristol Myers Squibb's Abecma.

Within MedTech, Johnson & Johnson competes with:

Its diversified business model provides exposure across multiple healthcare markets, reducing reliance on any single therapeutic category.

Bull Case: Why Johnson & Johnson's Long-Term Strategy Appears Intact

Several developments support the company's longer-term outlook.

First, oncology continues demonstrating robust commercial momentum, suggesting Johnson & Johnson has successfully developed replacement products ahead of significant patent expirations.

Second, management has now increased guidance twice during 2026, indicating confidence in business performance during the second half of the year.

Third, both major operating segments delivered positive growth simultaneously, reflecting balanced execution across pharmaceuticals and medical devices.

Finally, surpassing $100 billion in annual revenue would represent an important operational milestone, demonstrating that Johnson & Johnson can continue expanding despite significant patent losses.

Bear Case: What Investors Continue Monitoring

Despite the strong quarter, several risks remain.

The continued decline of Stelara revenue could remain a headwind for several quarters, requiring sustained strength from newer therapies.

Litigation surrounding talc products remains unresolved and could continue influencing investor sentiment irrespective of operating performance.

Competition across oncology is intensifying as pharmaceutical companies introduce new immunotherapies, antibody-drug conjugates and cell therapies.

Additionally, healthcare pricing reforms and reimbursement pressures may affect long-term profitability across the industry.

These factors help explain why investors remain cautious despite improved near-term financial performance.

Johnson & Johnson Outlook: Strong Fundamentals but Elevated Expectations

Johnson & Johnson's second-quarter 2026 results demonstrated continued operational execution across both Innovative Medicine and MedTech. Revenue growth exceeded expectations, oncology remained exceptionally strong, and management again increased its financial outlook.

However, equity markets often focus on future expectations rather than past performance. With the stock having appreciated significantly before earnings, investors evaluated not only the strong quarterly numbers but also the company's ongoing challenges, including patent expirations, litigation exposure and future pricing pressures.

The quarter reinforces Johnson & Johnson's ability to generate consistent operating growth while navigating industry headwinds. Whether the company's expanding oncology portfolio can continue offsetting revenue erosion from mature products will likely remain one of the most closely watched themes over the coming quarters.

Frequently Asked Questions (FAQs)

Why did Johnson & Johnson (NYSE: JNJ) stock fall after strong Q2 2026 earnings?

The shares declined despite stronger results because investors had already priced in much of the positive outlook following a strong year-to-date rally. Profit-taking, ongoing litigation concerns and patent-related revenue declines also weighed on sentiment.

What were Johnson & Johnson's Q2 2026 revenue and earnings?

Johnson & Johnson reported revenue of $25.31 billion, up 6.6% year over year, and adjusted earnings per share of $2.90, exceeding analyst expectations.

Why did Johnson & Johnson raise its 2026 guidance?

The company cited continued strength across its Innovative Medicine and MedTech businesses, particularly robust growth in its oncology portfolio, which supported higher revenue and earnings expectations.

Which products drove Johnson & Johnson's pharmaceutical growth?

The primary growth drivers were Darzalex, Carvykti, and Rybrevant/Lazcluze, all of which recorded strong year-over-year sales growth during the quarter.

What are the biggest risks facing Johnson & Johnson?

Key risks include continued revenue erosion from Stelara following loss of exclusivity, ongoing talc-related litigation, healthcare pricing reforms, competitive pressures in oncology and broader regulatory uncertainty.